CN108465125A - The tendon composite muscle in natural tissues source takes off the preparation method of cell material - Google Patents
The tendon composite muscle in natural tissues source takes off the preparation method of cell material Download PDFInfo
- Publication number
- CN108465125A CN108465125A CN201810295262.3A CN201810295262A CN108465125A CN 108465125 A CN108465125 A CN 108465125A CN 201810295262 A CN201810295262 A CN 201810295262A CN 108465125 A CN108465125 A CN 108465125A
- Authority
- CN
- China
- Prior art keywords
- pbs buffer
- buffer solution
- muscle
- tendon
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000003205 muscle Anatomy 0.000 title claims abstract description 90
- 239000000463 material Substances 0.000 title claims abstract description 80
- 210000002435 tendon Anatomy 0.000 title claims abstract description 72
- 239000002131 composite material Substances 0.000 title claims abstract description 49
- 210000001519 tissue Anatomy 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 239000007853 buffer solution Substances 0.000 claims abstract description 45
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims abstract description 18
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims abstract description 8
- 241000124008 Mammalia Species 0.000 claims abstract description 4
- 230000002255 enzymatic effect Effects 0.000 claims abstract 4
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 claims abstract 4
- 239000000243 solution Substances 0.000 claims description 31
- 229930182555 Penicillin Natural products 0.000 claims description 25
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 25
- 229940049954 penicillin Drugs 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 229920004890 Triton X-100 Polymers 0.000 claims description 6
- 239000013504 Triton X-100 Substances 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000012535 impurity Substances 0.000 claims description 6
- 238000003307 slaughter Methods 0.000 claims description 2
- 230000000845 anti-microbial effect Effects 0.000 claims 7
- 239000012530 fluid Substances 0.000 claims 7
- 206010010254 Concussion Diseases 0.000 claims 2
- 230000009514 concussion Effects 0.000 claims 2
- 238000006911 enzymatic reaction Methods 0.000 claims 1
- 238000011010 flushing procedure Methods 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 abstract description 8
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 abstract description 8
- 210000004027 cell Anatomy 0.000 abstract description 8
- 210000002744 extracellular matrix Anatomy 0.000 abstract description 8
- 230000005847 immunogenicity Effects 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 208000029549 Muscle injury Diseases 0.000 abstract description 3
- 230000006378 damage Effects 0.000 abstract description 2
- 238000010129 solution processing Methods 0.000 abstract 1
- 210000003537 structural cell Anatomy 0.000 abstract 1
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 46
- 230000000844 anti-bacterial effect Effects 0.000 description 28
- 239000000872 buffer Substances 0.000 description 27
- 229960005322 streptomycin Drugs 0.000 description 23
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 238000001514 detection method Methods 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 11
- 230000007547 defect Effects 0.000 description 11
- 230000008929 regeneration Effects 0.000 description 11
- 238000011069 regeneration method Methods 0.000 description 11
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 10
- 238000010586 diagram Methods 0.000 description 9
- 102000016911 Deoxyribonucleases Human genes 0.000 description 8
- 108010053770 Deoxyribonucleases Proteins 0.000 description 8
- 239000000835 fiber Substances 0.000 description 7
- 210000001087 myotubule Anatomy 0.000 description 7
- 239000007788 liquid Substances 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 230000001172 regenerating effect Effects 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 210000001361 achilles tendon Anatomy 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 241000282887 Suidae Species 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000009756 muscle regeneration Effects 0.000 description 3
- 229920002113 octoxynol Polymers 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- FCZYGJBVLGLYQU-UHFFFAOYSA-M sodium;2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethanesulfonate Chemical compound [Na+].CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCS([O-])(=O)=O)C=C1 FCZYGJBVLGLYQU-UHFFFAOYSA-M 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3633—Extracellular matrix [ECM]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
- A61L27/367—Muscle tissue, e.g. sphincter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3691—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by physical conditions of the treatment, e.g. applying a compressive force to the composition, pressure cycles, ultrasonic/sonication or microwave treatment, lyophilisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/30—Materials or treatment for tissue regeneration for muscle reconstruction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
技术领域technical field
本发明主要涉及用于全身骨骼肌肉组织修复及其再生的医学领域,具体是一种天然组织来源的肌腱复合肌肉脱细胞材料的制备,该生物支架在去除免疫原性的细胞成分同时,较好的保留了天然的肌腱复合肌肉的分层结构、细胞外基质成分、具有较强的力学性能,并且该材料能促进肌肉缺损的修复和再生。The present invention mainly relates to the medical field for repairing and regenerating skeletal muscle tissue of the whole body, in particular to the preparation of a tendon composite muscle decellularized material derived from natural tissue. It retains the layered structure of the natural tendon compound muscle, extracellular matrix components, has strong mechanical properties, and the material can promote the repair and regeneration of muscle defects.
背景技术Background technique
由创伤,不合理的运动,退行性疾病等造成的肌肉损伤在临床上十分常见,严重影响患者的生活质量。组织工程的广泛应用在攻克这方面的疾病中取得了一定的进步,目前的研究主要集中在制备一个单纯的肌肉支架来诱导肌纤维再生,但是效果并不理想。第一:生理状况下,肌纤维与肌腱或者肌筋膜相连接,而正是通过肌肉肌腱的连接部分形成一个的网络结构,单个肌纤维形成收缩总和,产生高效的运动,而单纯的肌肉支架缺乏这个结构。第二:单纯的肌肉支架力学性能较差(最大应力为0.1-5Mpa),易在大块腹部缺陷或肢体肌肉缺陷的高张力下破裂,而肌腱支架的最大应力水平为30-1000Mpa,它能提供稳定的力学支持。因此,肌腱复合肌肉支架,具有完整的机械传导系统更适合肌肉组织工程。Muscle injuries caused by trauma, unreasonable exercise, degenerative diseases, etc. are very common in clinical practice and seriously affect the quality of life of patients. The widespread application of tissue engineering has made some progress in overcoming this disease. Current research is mainly focused on preparing a simple muscle scaffold to induce muscle fiber regeneration, but the effect is not ideal. First: Under physiological conditions, muscle fibers are connected to tendons or myofascia, and it is through the connection of muscles and tendons that a network structure is formed, and a single muscle fiber forms a sum of contractions to produce efficient movement, while a simple muscle scaffold lacks this structure. Second: The mechanical properties of simple muscle scaffolds are poor (maximum stress is 0.1-5Mpa), and they are easy to rupture under high tension of large abdominal defects or limb muscle defects, while the maximum stress level of tendon scaffolds is 30-1000Mpa, which can Provide stable mechanical support. Therefore, the tendon composite muscle scaffold with a complete mechanical conduction system is more suitable for muscle tissue engineering.
由于天然的肌腱复合肌肉组织,尤其是两者的交界部分相当复杂,目前很少有研究能创造完全模拟天然的肌腱复合肌肉结构的支架,无法实现很好的肌肉缺损的修复和再生。脱细胞技术能提供一种潜在的解决方案,脱细胞支架在去除免疫原性的细胞组分同时,较好的模拟天然的组织结构并保留细胞外基质成分,目前肌腱复合肌肉脱细胞支架还未见报道。因此本发明通过创新的脱细胞技术制备了一种天然的肌腱复合肌肉脱细胞支架,在去除细胞的同时,最大化模拟了天然的肌腱复合肌肉结构,证明了该支架具有极低的免疫原性,具有较强的力学性能,较好的保留了天然的肌腱复合肌肉组织的细胞外基质组分,并且证实该支架在体内能很好的修复的肌肉缺损,在肌肉再生组织工程中有极大的意义。Due to the complexity of the natural tendon-composite muscle tissue, especially the junction between the two, few studies have been able to create a scaffold that completely simulates the natural tendon-composite muscle structure, which cannot achieve good repair and regeneration of muscle defects. Decellularization technology can provide a potential solution. While removing immunogenic cellular components, decellularized scaffolds can better simulate the natural tissue structure and retain extracellular matrix components. Currently, decellularized scaffolds for tendon and muscle have not yet See report. Therefore, the present invention prepares a natural tendon composite muscle decellularized scaffold through innovative decellularization technology, which simulates the natural tendon composite muscle structure to the greatest extent while removing cells, and proves that the scaffold has extremely low immunogenicity , has strong mechanical properties, better retains the extracellular matrix components of the natural tendon compound muscle tissue, and proves that the scaffold can well repair muscle defects in vivo, and has a great role in muscle regeneration tissue engineering meaning.
发明内容:Invention content:
本发明目的在于填补现有技术中,尚无肌腱复合肌肉支架制备的报道,提供一种具有极低免疫原性的,良好的力学性能的,较好保留细胞外基质组分的,并能促进肌肉缺损再生的脱细胞肌腱复合肌肉支架的制备方法。The purpose of the present invention is to fill in the prior art, there is no report on the preparation of tendon composite muscle scaffolds, to provide one with extremely low immunogenicity, good mechanical properties, better retain extracellular matrix components, and can promote Preparation method of decellularized tendon composite muscle scaffold for muscle defect regeneration.
天然组织来源的肌腱复合肌肉脱细胞材料的制备方法,该方法具体包括以下步骤:A method for preparing a tendon compound muscle decellularized material derived from natural tissue, the method specifically includes the following steps:
(1)取宰杀12h以内任意哺乳动物的肌腱复合肌肉组织,用剪刀除去肌肉以及肌腱上的脂肪,用含蛋白酶抑制剂的PBS缓冲液漂洗3次,每次30min,去除血液,贴附的脂肪碎片和其他杂质;(1) Take the tendon compound muscle tissue of any mammal within 12 hours of slaughter, remove the fat on the muscle and tendon with scissors, rinse with PBS buffer containing protease inhibitors for 3 times, each time for 30 minutes, and remove blood and attached fat debris and other impurities;
(2)在含蛋白酶抑制剂的PBS缓冲液中,在4℃温度下用摇床100rpm震荡24-48小时;然后用液氮冻融3个循环;(2) In PBS buffer containing protease inhibitors, shake at 100 rpm on a shaker at 4°C for 24-48 hours; then freeze and thaw with liquid nitrogen for 3 cycles;
(3)在KCL的PBS缓冲液中,加入混合抗菌液,在4℃温度下用摇床100rpm震荡2-12小时;(3) In the PBS buffer solution of KCL, add the mixed antibacterial solution, shake with a shaker at 100 rpm for 2-12 hours at a temperature of 4°C;
(4)在KI的PBS缓冲液中,加入混合抗菌液,在4℃温度下用摇床100rpm震荡2-12小时;(4) Add the mixed antibacterial solution to the PBS buffer solution of KI, and shake it with a shaker at 100 rpm for 2-12 hours at a temperature of 4°C;
(5)在含Triton X的PBS缓冲液中,加入混合抗菌液,在4℃温度下用摇床100rpm震荡24-48小时;(5) In the PBS buffer solution containing Triton X, add the mixed antibacterial solution, and shake with a shaker at 100 rpm for 24-48 hours at a temperature of 4°C;
(6)在含SDS的PBS缓冲液中,加入混合抗菌液,在4℃温度下用摇床100rpm震荡24-48小时;(6) In the PBS buffer solution containing SDS, add the mixed antibacterial solution, and shake with a shaker at 100 rpm for 24-48 hours at a temperature of 4°C;
(7)在含DNA酶的PBS缓冲液中,加入混合抗菌液,在37℃温度下用摇床120rpm震荡12-24小时;(7) In the PBS buffer solution containing DNase, add the mixed antibacterial solution, and shake with a shaker at 120 rpm for 12-24 hours at a temperature of 37 ° C;
步骤(2)-(7)中,每个步骤完成后均用生理盐水冲洗8小时。In steps (2)-(7), rinse with physiological saline for 8 hours after each step is completed.
作为优选,所述的含蛋白酶抑制剂的PBS缓冲液中蛋白酶抑制剂浓度为10-50KIU/ml。As a preference, the protease inhibitor concentration in the PBS buffer containing the protease inhibitor is 10-50 KIU/ml.
作为优选,所述的含KCL的PBS缓冲液为浓度0.1M-1M的KCL的PBS缓冲液。Preferably, the PBS buffer containing KCL is a PBS buffer containing KCL at a concentration of 0.1M-1M.
作为优选,所述的含KI的PBS缓冲液为浓度1M-1.5M的KI的PBS缓冲液。Preferably, the KI-containing PBS buffer is a KI-containing PBS buffer with a concentration of 1M-1.5M.
作为优选,所述的含Triton X的PBS缓冲液为浓度0.05%-2%的Triton X-100或Triton X-200的PBS缓冲液。Preferably, the PBS buffer solution containing Triton X is a PBS buffer solution with a concentration of 0.05%-2% Triton X-100 or Triton X-200.
作为优选,所述的含SDS的PBS缓冲液为浓度0.02%-0.25%的SDS的PBS缓冲液。Preferably, the PBS buffer containing SDS is a PBS buffer containing SDS at a concentration of 0.02%-0.25%.
作为优选,所述的含DNA酶的PBS缓冲液为浓度为1-2mg/mL DNA酶PBS缓冲液。Preferably, the PBS buffer solution containing DNase is a PBS buffer solution with a concentration of 1-2 mg/mL DNase.
作为优选,所述的混合抗菌液中青霉素和链霉素的浓度分别为20K IU/ml,20g/ml;青霉素和链霉素的比例为1:1,加入的混合抗菌液与原溶液体积比为1:1。As preferably, the concentrations of penicillin and streptomycin in the mixed antibacterial solution are 20K IU/ml and 20g/ml respectively; the ratio of penicillin and streptomycin is 1:1, and the volume ratio of the added mixed antibacterial solution to the original solution is 1:1.
作为优选,所述的液氮冻融3个循环中循环的温度为从-80℃~37℃。Preferably, the temperature in the three cycles of freezing and thawing of liquid nitrogen is from -80°C to 37°C.
针对目前用于肌肉修复和再生的材料及其制备方法存在的缺陷与不足,发明人建立了一种天然组织来源的肌腱复合肌肉脱细胞材料的制备方法,该方法将哺乳动物任意大小的肌腱复合肌肉组织经含蛋白酶抑制剂的PBS、含KCl的PBS缓冲液、含KI的PBS缓冲液、含Triton X的PBS缓冲液、含SDS的PBS缓冲液、含DNA酶的PBS缓冲液处理,获得天然组织来源的肌腱复合肌肉脱细胞材料。本发明能对组织上的细胞进行完全去细胞化处理,且条件温和、无ECM损害、快速稳定。所得的材料,不仅最大限度的模拟了天然的肌腱复合肌肉的分层结构、较好的保留了细胞外基质成分、还具有极低的免疫原性,较强的力学性能等优点,可用于修复临床上各类病因造成的肌肉损伤、退变相关疾病。Aiming at the deficiencies and deficiencies in the materials and preparation methods currently used for muscle repair and regeneration, the inventors have established a method for the preparation of tendon composite muscle decellularized materials derived from natural tissues. This method composites tendons of any size in mammals Muscle tissue was treated with PBS buffer containing protease inhibitors, PBS buffer containing KCl, PBS buffer containing KI, PBS buffer containing Triton X, PBS buffer containing SDS, and PBS buffer containing DNase to obtain natural Tissue-derived tendon-composite muscle decellularized material. The invention can completely decellularize the cells on the tissue with mild conditions, no ECM damage, and rapid stability. The obtained material not only simulates the layered structure of the natural tendon compound muscle to the greatest extent, but also retains the extracellular matrix components better, and also has the advantages of extremely low immunogenicity and strong mechanical properties, which can be used for repairing Clinically, muscle damage and degeneration related diseases caused by various etiologies.
相对于现有技术,本发明的显著进步在于:Compared with prior art, remarkable progress of the present invention is:
(1)本发明通过脱细胞技术制备的肌腱复合肌肉脱细胞材料在去除异种/异体细胞的同时,可较好保留原先ECM的完整性,可以最大限度的模拟正常肌腱复合肌肉分层结构,细胞外基质成分,微观结构。(1) The decellularized tendon composite muscle material prepared by the decellularization technology in the present invention can better retain the integrity of the original ECM while removing heterogeneous/alternative cells, and can simulate the layered structure of normal tendon composite muscle to the greatest extent. Extracellular matrix composition, microstructure.
(2)本发明材料不含细胞、细胞核、DNA等抗原性物质,具有极低的免疫排斥反应,具有很好的生物相容性。(2) The material of the present invention does not contain antigenic substances such as cells, nuclei, and DNA, has extremely low immune rejection, and has good biocompatibility.
(3)本发明材料因复合了肌腱组织,具有较强的生物力学性能。(3) The material of the present invention has strong biomechanical properties due to the composite tendon tissue.
(4)本发明材料在肌肉缺损的模型中能促进肌肉再生,在肌肉再生组织工程中有极大的意义。(4) The material of the present invention can promote muscle regeneration in the model of muscle defect, and has great significance in muscle regeneration tissue engineering.
附图说明Description of drawings
图1是本发明材料大体外观图;Fig. 1 is the general appearance figure of material of the present invention;
图2是本发明材料HE染色无细胞及无细胞核成分残留图;Fig. 2 is a cell-free and cell-free nuclear component residue diagram of the material of the present invention stained with HE;
图3是本发明材料DNA定量检测几乎不含有DNA成分图;Fig. 3 is the material DNA quantitative detection of the present invention and almost does not contain the DNA component diagram;
图4是本发明材料胶原成分定性(Masson三色染色)以及定量检测保留大量胶原成分图;Fig. 4 is a qualitative (Masson's trichrome staining) and quantitative detection of the collagen components of the material of the present invention to retain a large amount of collagen components;
图5是本发明材料扫描电镜证明纤维排布以及空间立体结构保留图;Fig. 5 is a scanning electron microscope proof of the material of the present invention showing fiber arrangement and spatial three-dimensional structure retention;
图6是本发明材料生物力学特性检测证明极强的生物力学图;Fig. 6 is the extremely strong biomechanical diagram proved by the detection of the biomechanical properties of the material of the present invention;
图7是本发明材料体外复细胞HE染色检测证明极好的生物相容性图;Fig. 7 is the excellent biocompatibility diagram proved by HE staining test of the material of the present invention in vitro;
图8是本发明材料体外复细胞PCR定量检测肌纤维产生基因表达图;Fig. 8 is the quantitative detection of myofiber production gene expression diagram by multiple cell PCR in vitro of the material of the present invention;
图9是本材料大鼠体内皮下包埋,7天和30天HE染色以及CD86,CD163免疫组化染色证明较少的炎症细胞浸润,极低的免疫原性图;Figure 9 is a picture of subcutaneous embedding of this material in rats, 7 days and 30 days HE staining and CD86, CD163 immunohistochemical staining proves less inflammatory cell infiltration and extremely low immunogenicity;
图10是本发明材料移植兔子大面积肌肉缺损7天和30天的HE以及Masson染色肌纤维再生证实体内可促进肌肉修复再生图。Fig. 10 is a picture of HE and Masson staining of muscle fiber regeneration confirmed by the material of the present invention transplanted into rabbits with large area of muscle defect for 7 days and 30 days, which proves that it can promote muscle repair and regeneration in vivo.
具体实施方案specific implementation plan
下面结合附图及实施例对本发明进行详细描述,但本发明的实施不仅限于此。The present invention will be described in detail below in conjunction with the accompanying drawings and embodiments, but the implementation of the present invention is not limited thereto.
实施例1:天然组织来源的肌腱复合肌肉脱细胞材料的制备方法和再生修复研究Example 1: Preparation method and regenerative repair research of tendon composite muscle decellularized material derived from natural tissue
1.制备肌腱复合肌肉脱细胞材料1. Preparation of Tendon Composite Muscle Decellularized Material
(1)取材:在猪的跟腱中取肌腱复合肌肉材料,按纤维方向将肌腱切成长度宽度和厚度分别为2*1.0*0.2cm大小,肌肉长宽高均为0.3cm,用含10K IU/ml蛋白酶抑制剂的生理盐水漂洗3次,每次30min,无菌PBS充分漂洗去除血液和其他杂质。(1) Materials: Take the tendon compound muscle material from the Achilles tendon of pigs, cut the tendon into length, width and thickness of 2*1.0*0.2cm according to the fiber direction, and the length, width and height of the muscle are 0.3cm. IU/ml protease inhibitor normal saline rinsed 3 times, 30min each time, fully rinsed with sterile PBS to remove blood and other impurities.
(2)脱细胞步骤如下:(2) The decellularization steps are as follows:
①、在含10K IU/ml蛋白酶抑制剂的PBS缓冲液中,低温(4℃)摇床100rpm震荡48小时,然后用液氮冻融3个循环(-80℃/37℃);①. In the PBS buffer solution containing 10K IU/ml protease inhibitor, shake at 100 rpm on a low temperature (4°C) shaker for 48 hours, and then freeze and thaw with liquid nitrogen for 3 cycles (-80°C/37°C);
②、在含0.1M KCL的PBS缓冲液中,1:1加入青霉素和链霉素(20KIU/ml,20g/ml)混合抗菌液,低温(4℃)摇床100rpm震荡6小时;②. In the PBS buffer containing 0.1M KCL, add penicillin and streptomycin (20KIU/ml, 20g/ml) mixed antibacterial solution 1:1, and shake at 100rpm on a low-temperature (4°C) shaker for 6 hours;
③、在含1M KI的PBS缓冲液中,1:1加入青霉素和链霉素(20KIU/ml,20g/ml)混合抗菌液,低温(4℃)摇床100rpm震荡6小时;③. In PBS buffer containing 1M KI, add penicillin and streptomycin (20KIU/ml, 20g/ml) mixed antibacterial solution 1:1, and shake at 100rpm on a low temperature (4°C) shaker for 6 hours;
④、在浓度为0.05%的Triton X-100的PBS缓冲液中,1:1加入青霉素和链霉素(20KIU/ml,20g/ml)混合抗菌液,低温(4℃)摇床100rpm震荡24小时;④. Add penicillin and streptomycin (20KIU/ml, 20g/ml) mixed antibacterial solution in 0.05% Triton X-100 PBS buffer solution at a ratio of 1:1, shake at 100rpm on a low-temperature (4°C) shaker for 24 Hour;
⑤、在浓度为0.02%的含SDS的PBS缓冲液中,1:1加入青霉素和链霉素(20KIU/ml,20g/ml)混合抗菌液,低温(4℃)摇床100rpm震荡24小时;⑤. Add penicillin and streptomycin (20KIU/ml, 20g/ml) mixed antibacterial solution in 0.02% SDS-containing PBS buffer solution at a ratio of 1:1, shake at 100rpm on a low-temperature (4°C) shaker for 24 hours;
⑥、在浓度为1mg/ml的含DNA酶的PBS缓冲液中,1:1加入青霉素和链霉素(20KIU/ml,20g/ml)混合抗菌液,37℃摇床100rpm震荡12小时,即可得到肌腱复合肌肉脱细胞材料。⑥. Add penicillin and streptomycin (20KIU/ml, 20g/ml) mixed antibacterial solution in 1mg/ml DNase-containing PBS buffer solution at a ratio of 1:1, shake at 100rpm on a shaker at 37°C for 12 hours, that is Tendon composite muscle decellularized material is available.
注:完成每一步骤后均用生理盐水冲洗8小时。Note: Rinse with saline for 8 hours after each step.
2.天然组织来源的肌腱复合肌肉脱细胞材料细胞去除评定2. Evaluation of Cell Removal from Natural Tissue-Derived Tendon Composite Muscle Decellularized Materials
图1是本发明材料的大体外观图(*表示为肌腱部分;△表示为肌肉部分);图2是本发明材料HE染色无细胞及无细胞核成分残留图;图3是本发明材料DNA定量检测几乎不含有DNA成分图。Fig. 1 is a general appearance diagram of the material of the present invention (* represents the tendon part; △ represents the muscle part); Fig. 2 is a cell-free and non-nuclear component residual image of the material of the present invention stained with HE; Fig. 3 is the DNA quantitative detection of the material of the present invention Almost no DNA composition map.
3.肌腱复合肌肉脱细胞材料细胞外基质保留的评估3. Evaluation of Extracellular Matrix Retention of Tendon-Compound Muscle Decellularized Materials
图4是本发明材料胶原成分定性定量检测保留大量胶原成分图;图5是本发明材料扫描电镜证明纤维排布以及空间立体结构保留图(箭头所指为纤维排布方向)。Fig. 4 is a graph of qualitative and quantitative detection of collagen components of the material of the present invention to retain a large amount of collagen components; Fig. 5 is a diagram of fiber arrangement and spatial three-dimensional structure retention of the material of the present invention as evidenced by scanning electron microscopy (arrows indicate the direction of fiber arrangement).
4.肌腱复合肌肉脱细胞材料生物力学性能的评估4. Evaluation of Biomechanical Properties of Tendon Composite Muscle Decellularized Materials
图6是本发明材料生物力学特性检测(极限拉应力,弹性系数以及张力-压力曲线)证明极强的生物力学图。Fig. 6 is a very strong biomechanical diagram proved by the detection of the biomechanical properties of the material of the present invention (ultimate tensile stress, elastic coefficient and tension-pressure curve).
5.肌腱复合肌肉脱细胞材料良好的生物相容性、极低免疫原性测定5. Determination of good biocompatibility and extremely low immunogenicity of tendon composite muscle acellular material
图7是本发明材料体外复细胞HE染色检测证明极好的生物相容性图;图8是本发明材料体外复细胞PCR定量检测肌纤维产生基因表达图;图9是本材料大鼠体内皮下包埋,7天和30天HE染色以及CD86,CD163免疫组化染色证明较少的炎症细胞浸润,极低的免疫原性图。Fig. 7 is the excellent biocompatibility figure proved by the HE staining detection of the material of the present invention in vitro; Fig. 8 is the gene expression diagram of the quantitative detection of muscle fibers produced by PCR of the material of the present invention in vitro; Fig. 9 is the subcutaneous bag of the material in rats Buried, 7 days and 30 days HE staining and CD86, CD163 immunohistochemical staining proved less inflammatory cell infiltration, very low immunogenicity figure.
6.肌腱复合肌肉脱细胞材料促进肌肉缺损修复与再生6. Tendon composite muscle decellularized material promotes the repair and regeneration of muscle defects
图10是本发明材料移植兔子大面积肌肉缺损7天和30天的HE以及Masson染色肌纤维再生证实体内可促进肌肉修复再生图。Fig. 10 is a picture of HE and Masson staining of muscle fiber regeneration confirmed by the material of the present invention transplanted into rabbits with large area of muscle defect for 7 days and 30 days, which proves that it can promote muscle repair and regeneration in vivo.
实施例2:脱细胞肌腱联合肌肉材料的制备和再生修复研究Example 2: Preparation and regenerative repair of decellularized tendon and muscle materials
1.制备肌腱复合肌肉脱细胞材料1. Preparation of Tendon Composite Muscle Decellularized Material
(1)取材:在猪的跟腱中取肌腱复合肌肉材料,按纤维方向将肌腱切成长度宽度和厚度分别为4.0*2.0*0.4cm大小,肌肉长宽高均为0.6cm,用含10K IU/ml蛋白酶抑制剂的生理盐水漂洗3次,每次30min,无菌PBS充分漂洗去除血液和其他杂质。(1) Materials: Take the tendon compound muscle material from the Achilles tendon of pigs, cut the tendon into length, width and thickness of 4.0*2.0*0.4cm according to the fiber direction, and the length, width and height of the muscle are 0.6cm. IU/ml protease inhibitor normal saline rinsed 3 times, 30min each time, fully rinsed with sterile PBS to remove blood and other impurities.
(2)脱细胞步骤如下:(2) The decellularization steps are as follows:
①、在含30K IU/ml蛋白酶抑制剂的PBS缓冲液中,低温(4℃)摇床100rpm震荡48小时,然后用液氮冻融3个循环(-80℃/37℃);①. In the PBS buffer solution containing 30K IU/ml protease inhibitor, shake at 100 rpm for 48 hours on a low-temperature (4°C) shaker, and then freeze and thaw with liquid nitrogen for 3 cycles (-80°C/37°C);
②、在含0.5M KCL的PBS缓冲液中,1:1加入青霉素和链霉素(20KIU/ml,20g/ml)混合抗菌液,低温(4℃)摇床100rpm震荡12小时;②. In the PBS buffer containing 0.5M KCL, add penicillin and streptomycin (20KIU/ml, 20g/ml) mixed antibacterial solution 1:1, and shake at 100rpm on a low-temperature (4°C) shaker for 12 hours;
③、在含1.3M KI的PBS缓冲液中,1:1加入青霉素和链霉素(20KIU/ml,20g/ml)混合抗菌液,低温(4℃)摇床100rpm震荡12小时;③. In the PBS buffer solution containing 1.3M KI, add penicillin and streptomycin (20KIU/ml, 20g/ml) mixed antibacterial solution 1:1, and shake at 100rpm on a low-temperature (4°C) shaker for 12 hours;
④、在浓度为0.2%的Triton X-100的PBS缓冲液中,1:1加入青霉素和链霉素(20KIU/ml,20g/ml)混合抗菌液,低温(4℃)摇床100rpm震荡24小时;④. Add penicillin and streptomycin (20KIU/ml, 20g/ml) mixed antibacterial solution in 0.2% Triton X-100 PBS buffer solution at a ratio of 1:1, shake at 100rpm on a low temperature (4°C) shaker for 24 Hour;
⑤、在浓度为0.05%的含SDS的PBS缓冲液中,1:1加入青霉素和链霉素(20KIU/ml,20g/ml)混合抗菌液,低温(4℃)摇床100rpm震荡24小时;⑤. Add penicillin and streptomycin (20KIU/ml, 20g/ml) mixed antibacterial solution in 0.05% PBS buffer solution containing SDS at a concentration of 0.05%, shake at 100rpm on a low temperature (4°C) shaker for 24 hours;
⑥、在浓度为1.5mg/ml的含DNA酶的PBS缓冲液中,1:1加入青霉素和链霉素(20KIU/ml,20g/ml)混合抗菌液,37℃摇床100rpm震荡12小时,即可得到肌腱复合肌肉脱细胞材料。其余参考实施例1的方法进行,得到天然组织来源的肌腱复合肌肉脱细胞材料。⑥. Add penicillin and streptomycin (20KIU/ml, 20g/ml) mixed antibacterial solution 1:1 to 1.5mg/ml DNase-containing PBS buffer, and shake at 100rpm for 12 hours on a shaker at 37°C. The tendon compound muscle decellularized material can be obtained. The rest were carried out with reference to the method of Example 1 to obtain the tendon composite muscle decellularized material derived from natural tissue.
实施例3:天然组织来源的肌腱复合肌肉脱细胞材料的制备方法和再生修复研究Example 3: Preparation method and regenerative repair research of tendon composite muscle decellularized material derived from natural tissue
1.制备肌腱复合肌肉脱细胞材料1. Preparation of Tendon Composite Muscle Decellularized Material
(1)取材:在羊的跟腱中取肌腱复合肌肉材料,按纤维方向将肌腱切成长度宽度和厚度分别为4.0*2.0*0.6cm大小,肌肉长宽高均为0.6cm,用含10K IU/ml蛋白酶抑制剂的生理盐水漂洗3次,每次30min,无菌PBS充分漂洗去除血液和其他杂质。(1) Materials: The tendon compound muscle material was taken from the Achilles tendon of sheep, and the tendon was cut into length, width and thickness according to the fiber direction of 4.0*2.0*0.6cm, and the length, width and height of the muscle were 0.6cm. IU/ml protease inhibitor normal saline rinsed 3 times, 30min each time, fully rinsed with sterile PBS to remove blood and other impurities.
(2)脱细胞步骤如下:(2) The decellularization steps are as follows:
①、在含30K IU/ml蛋白酶抑制剂的PBS缓冲液中,低温(4℃)摇床100rpm震荡36小时,然后用液氮冻融3个循环(-80℃/37℃);①. In the PBS buffer solution containing 30K IU/ml protease inhibitor, shake at 100 rpm for 36 hours on a low-temperature (4°C) shaker, and then freeze and thaw with liquid nitrogen for 3 cycles (-80°C/37°C);
②、在含0.5M KCL的PBS缓冲液中,1:1加入青霉素和链霉素(20KIU/ml,20g/ml)混合抗菌液,低温(4℃)摇床100rpm震荡12小时;②. In the PBS buffer containing 0.5M KCL, add penicillin and streptomycin (20KIU/ml, 20g/ml) mixed antibacterial solution 1:1, and shake at 100rpm on a low-temperature (4°C) shaker for 12 hours;
③、在含1.3M KI的PBS缓冲液中,1:1加入青霉素和链霉素(20KIU/ml,20g/ml)混合抗菌液,低温(4℃)摇床100rpm震荡2小时;③. In the PBS buffer containing 1.3M KI, add penicillin and streptomycin (20KIU/ml, 20g/ml) mixed antibacterial solution 1:1, and shake at 100rpm on a low-temperature (4°C) shaker for 2 hours;
④、在浓度为0.5%的Triton X-100的PBS缓冲液中,1:1加入青霉素和链霉素(20KIU/ml,20g/ml)混合抗菌液,低温(4℃)摇床100rpm震荡48小时;④. Add penicillin and streptomycin (20KIU/ml, 20g/ml) mixed antibacterial solution in 0.5% Triton X-100 PBS buffer solution at a ratio of 1:1. Hour;
⑤、在浓度为0.1%的含SDS的PBS缓冲液中,1:1加入青霉素和链霉素(20KIU/ml,20g/ml)混合抗菌液,低温(4℃)摇床100rpm震荡30小时;⑤. Add penicillin and streptomycin (20KIU/ml, 20g/ml) mixed antibacterial solution in 0.1% PBS buffer containing SDS at a concentration of 1:1, shake at 100rpm on a low temperature (4°C) shaker for 30 hours;
⑥、在浓度为1.5mg/ml的含DNA酶的PBS缓冲液中,1:1加入青霉素和链霉素(20KIU/ml,20g/ml)混合抗菌液,37℃摇床100rpm震荡12小时,即可得到肌腱复合肌肉脱细胞材料。其余参考实施例1的方法进行,得到天然组织来源的肌腱复合肌肉脱细胞材料。⑥. Add penicillin and streptomycin (20KIU/ml, 20g/ml) mixed antibacterial solution 1:1 to 1.5mg/ml DNase-containing PBS buffer, and shake at 100rpm for 12 hours on a shaker at 37°C. The tendon compound muscle decellularized material can be obtained. The rest were carried out with reference to the method of Example 1 to obtain the tendon composite muscle decellularized material derived from natural tissue.
实施例4:天然组织来源的肌腱复合肌肉脱细胞材料的制备方法和再生修复研究Example 4: Preparation method and regenerative repair research of tendon composite muscle decellularized material derived from natural tissue
1.制备肌腱复合肌肉脱细胞材料1. Preparation of Tendon Composite Muscle Decellularized Material
(1)取材:在猪的跟腱中取肌腱复合肌肉材料,按纤维方向将肌腱切成长度宽度和厚度分别为4*2.0*0.8cm大小,肌肉长宽高均为0.6cm,用含10K IU/ml蛋白酶抑制剂的生理盐水漂洗3次,每次30min,无菌PBS充分漂洗去除血液和其他杂质。(1) Materials: The tendon compound muscle material was taken from the Achilles tendon of pigs, and the tendon was cut into length, width and thickness according to the fiber direction to be 4*2.0*0.8cm in size, and the length, width, and height of the muscle were both 0.6cm. IU/ml protease inhibitor normal saline rinsed 3 times, 30min each time, fully rinsed with sterile PBS to remove blood and other impurities.
(2)脱细胞步骤如下:(2) The decellularization steps are as follows:
①、在含50K IU/ml蛋白酶抑制剂的PBS缓冲液中,低温(4℃)摇床100rpm震荡48小时,然后用液氮冻融3个循环(-80℃/37℃);①. In the PBS buffer solution containing 50K IU/ml protease inhibitor, shake at 100rpm on a low temperature (4°C) shaker for 48 hours, and then freeze and thaw with liquid nitrogen for 3 cycles (-80°C/37°C);
②、在含1M KCL的PBS缓冲液中,1:1加入青霉素和链霉素(20KIU/ml,20g/ml)混合抗菌液,低温(4℃)摇床100rpm震荡2小时;②. In PBS buffer containing 1M KCL, add penicillin and streptomycin (20KIU/ml, 20g/ml) mixed antibacterial solution 1:1, and shake at 100rpm on a low temperature (4°C) shaker for 2 hours;
③、在含1.5M KI的PBS缓冲液中,1:1加入青霉素和链霉素(20KIU/ml,20g/ml)混合抗菌液,低温(4℃)摇床100rpm震荡12小时;③. In the PBS buffer containing 1.5M KI, add penicillin and streptomycin (20KIU/ml, 20g/ml) mixed antibacterial solution 1:1, and shake at 100rpm on a low-temperature (4°C) shaker for 12 hours;
④、在浓度为2%的Triton X-100的PBS缓冲液中,1:1加入青霉素和链霉素(20KIU/ml,20g/ml)混合抗菌液,低温(4℃)摇床100rpm震荡36小时;④. Add penicillin and streptomycin (20KIU/ml, 20g/ml) mixed antibacterial solution 1:1 to 2% Triton X-100 in PBS buffer, and shake at 100rpm on a low temperature (4°C) shaker for 36 Hour;
⑤、在浓度为0.25%的含SDS的PBS缓冲液中,1:1加入青霉素和链霉素(20KIU/ml,20g/ml)混合抗菌液,低温(4℃)摇床100rpm震荡48小时;⑤. Add penicillin and streptomycin (20KIU/ml, 20g/ml) mixed antibacterial solution in 0.25% PBS buffer containing SDS at a concentration of 1:1, shake at 100rpm on a low temperature (4°C) shaker for 48 hours;
⑥、在浓度为2mg/ml的含DNA酶的PBS缓冲液中,1:1加入青霉素和链霉素(20KIU/ml,20g/ml)混合抗菌液,37℃摇床100rpm震荡24小时,即可得到肌腱复合肌肉脱细胞材料。其余参考实施例1的方法进行,得到天然组织来源的肌腱复合肌肉脱细胞材料。⑥. Add penicillin and streptomycin (20KIU/ml, 20g/ml) mixed antibacterial solution 1:1 to the PBS buffer solution containing DNase at a concentration of 2mg/ml, shake at 100rpm on a shaker at 37°C for 24 hours, that is Tendon composite muscle decellularized material is available. The rest were carried out with reference to the method of Example 1 to obtain the tendon composite muscle decellularized material derived from natural tissue.
实施例5:脱细胞肌腱联合肌肉材料的制备和再生修复研究Example 5: Preparation and regenerative repair of decellularized tendon and muscle materials
取牛肌腱联合肌肉组织,骤④在浓度为2%的含Triton X-200的PBS缓冲液中,1:1加入青霉素和链霉素(20K IU/ml,20g/ml)混合抗菌液,低温(4℃)摇床100rpm震荡8小时。其余参考实施例1的方法进行,得到肌腱联合肌肉脱细胞材料。Take bovine tendon joint muscle tissue, step ④ add penicillin and streptomycin (20K IU/ml, 20g/ml) mixed antibacterial solution in 1:1 in the PBS buffer solution containing Triton X-200 with a concentration of 2%. (4° C.) Shake at 100 rpm for 8 hours. The rest were carried out with reference to the method of Example 1, and the decellularized material of tendon joint muscle was obtained.
对实施例2-5所得肌腱复合肌肉脱细胞材料分别进行组织学评价、抗原成分定量检测和力学检测,结果与实施例1类似,这表明可通过上述多种方法制得多种组织来源,多种组织大小的脱细胞肌腱复合肌肉材料,并且对该材料进行组织学评价、抗原成分定量检测检测均说明材料已经完全去除细胞成分,无明显抗原成分残留。同时用上述方法获得的肌腱复合肌肉脱细胞材料均具有极强的生物力学性能,极好的生物相容性。该肌腱复合肌肉脱细胞材料可以作为临床上促进肌肉缺损和病变修复再生的,安全可靠、有效、快速的生物材料。The tendon composite muscle decellularized materials obtained in Examples 2-5 were subjected to histological evaluation, quantitative detection of antigenic components and mechanical detection, and the results were similar to those in Example 1, which indicated that a variety of tissue sources could be obtained through the above-mentioned various methods, and many Acellular tendon composite muscle material with different tissue sizes, and the histological evaluation and quantitative detection of antigenic components of the material showed that the material had completely removed cellular components and no obvious antigenic components remained. At the same time, the tendon composite muscle decellularized materials obtained by the above method all have extremely strong biomechanical properties and excellent biocompatibility. The tendon composite muscle decellularized material can be used as a safe, reliable, effective and rapid biomaterial for clinically promoting the repair and regeneration of muscle defects and lesions.
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810295262.3A CN108465125A (en) | 2018-04-04 | 2018-04-04 | The tendon composite muscle in natural tissues source takes off the preparation method of cell material |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810295262.3A CN108465125A (en) | 2018-04-04 | 2018-04-04 | The tendon composite muscle in natural tissues source takes off the preparation method of cell material |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108465125A true CN108465125A (en) | 2018-08-31 |
Family
ID=63262805
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810295262.3A Pending CN108465125A (en) | 2018-04-04 | 2018-04-04 | The tendon composite muscle in natural tissues source takes off the preparation method of cell material |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108465125A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110227182A (en) * | 2019-01-17 | 2019-09-13 | 浙江大学医学院附属邵逸夫医院 | A kind of preparation method of gradient mineralising osteocyte extracellular matrix materials |
CN110237303A (en) * | 2019-06-27 | 2019-09-17 | 浙江大学医学院附属邵逸夫医院 | Preparation method of acellular periosteal matrix gel material derived from natural tissue |
CN110680955A (en) * | 2019-10-29 | 2020-01-14 | 浙江大学医学院附属邵逸夫医院 | Acellular material of acellular biphasic aponeurosis muscle from natural tissue source and preparation method |
CN111411077A (en) * | 2020-03-26 | 2020-07-14 | 浙江大学 | Application of small molecular substances in the preparation of reagents for maintaining the phenotype of tendon stem cells in vitro |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102727935A (en) * | 2012-07-19 | 2012-10-17 | 陕西博鸿生物科技有限公司 | Preparation method and device of duramater/spinal dural transplanting substitute |
CN103805555A (en) * | 2013-02-26 | 2014-05-21 | 中国人民解放军第二军医大学 | Skeletal muscle total-organ acellular matrix and preparation method and derivative medical products thereof |
CN104208750A (en) * | 2013-12-02 | 2014-12-17 | 四川大学华西医院 | Preparation method and application of acellular tendon material |
CN104288838A (en) * | 2014-10-22 | 2015-01-21 | 林贤丰 | Kit for obtaining multiple-organ and tissue extracellular matrix and using method of kit |
US20150337261A1 (en) * | 2013-01-14 | 2015-11-26 | Florida State University Research Foundation, Inc | Extracellular matrix derived from stem cells and methods for production |
CN105879120A (en) * | 2016-06-08 | 2016-08-24 | 浙江大学 | Preparation method of tendon conjunction bone decellularization material of natural tissue source |
CN107376022A (en) * | 2017-06-27 | 2017-11-24 | 浙江大学 | A kind of ovary in natural tissues source takes off cell material and preparation method thereof |
CN107715177A (en) * | 2016-07-26 | 2018-02-23 | 浙江大学 | The preparation method of the multiple de- cell material of nucleus pulposus cell modification intestinal mucosa lower floor |
-
2018
- 2018-04-04 CN CN201810295262.3A patent/CN108465125A/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102727935A (en) * | 2012-07-19 | 2012-10-17 | 陕西博鸿生物科技有限公司 | Preparation method and device of duramater/spinal dural transplanting substitute |
US20150337261A1 (en) * | 2013-01-14 | 2015-11-26 | Florida State University Research Foundation, Inc | Extracellular matrix derived from stem cells and methods for production |
CN103805555A (en) * | 2013-02-26 | 2014-05-21 | 中国人民解放军第二军医大学 | Skeletal muscle total-organ acellular matrix and preparation method and derivative medical products thereof |
CN104208750A (en) * | 2013-12-02 | 2014-12-17 | 四川大学华西医院 | Preparation method and application of acellular tendon material |
CN104288838A (en) * | 2014-10-22 | 2015-01-21 | 林贤丰 | Kit for obtaining multiple-organ and tissue extracellular matrix and using method of kit |
CN105879120A (en) * | 2016-06-08 | 2016-08-24 | 浙江大学 | Preparation method of tendon conjunction bone decellularization material of natural tissue source |
CN107715177A (en) * | 2016-07-26 | 2018-02-23 | 浙江大学 | The preparation method of the multiple de- cell material of nucleus pulposus cell modification intestinal mucosa lower floor |
CN107376022A (en) * | 2017-06-27 | 2017-11-24 | 浙江大学 | A kind of ovary in natural tissues source takes off cell material and preparation method thereof |
Non-Patent Citations (3)
Title |
---|
CHENCHEN ZHAO 等: "Preparation of decellularized biphasic hierarchical myotendinous", 《ACTA BIOMATERIALIA》 * |
JONATHAN M. FISHMAN 等: "Decellularized Rabbit Cricoarytenoid Dorsalis Muscle", 《ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY》 * |
张敏恒 主编: "《农药商品手册》", 31 August 1999, 沈阳出版社 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110227182A (en) * | 2019-01-17 | 2019-09-13 | 浙江大学医学院附属邵逸夫医院 | A kind of preparation method of gradient mineralising osteocyte extracellular matrix materials |
CN110237303A (en) * | 2019-06-27 | 2019-09-17 | 浙江大学医学院附属邵逸夫医院 | Preparation method of acellular periosteal matrix gel material derived from natural tissue |
CN110680955A (en) * | 2019-10-29 | 2020-01-14 | 浙江大学医学院附属邵逸夫医院 | Acellular material of acellular biphasic aponeurosis muscle from natural tissue source and preparation method |
CN110680955B (en) * | 2019-10-29 | 2021-12-14 | 浙江大学医学院附属邵逸夫医院 | Decellularized material and preparation method of acellular biphasic aponeurotic muscle derived from natural tissue |
CN111411077A (en) * | 2020-03-26 | 2020-07-14 | 浙江大学 | Application of small molecular substances in the preparation of reagents for maintaining the phenotype of tendon stem cells in vitro |
CN111411077B (en) * | 2020-03-26 | 2022-02-25 | 浙江大学 | Application of small molecular substance in preparation of reagent for maintaining tendon stem cell phenotype in vitro |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20180311410A1 (en) | Elastase treatment of tissue matrices | |
CN108465125A (en) | The tendon composite muscle in natural tissues source takes off the preparation method of cell material | |
Cissell et al. | Antigen removal for the production of biomechanically functional, xenogeneic tissue grafts | |
CN107376022B (en) | A kind of ovarian acellular material derived from natural tissue and preparation method thereof | |
CN104288838B (en) | Kit for obtaining multiple-organ and tissue extracellular matrix and using method of kit | |
JP6505088B2 (en) | Implant and method of manufacturing the same | |
CN105664255B (en) | A kind of synchondrosis bone in natural tissues source takes off the preparation method of cell material | |
AU2022241581A1 (en) | Compositions comprising mesenchymal stem cells and uses thereof | |
CN105188787A (en) | Method for decellularization of tissue grafts | |
CN105879120A (en) | Preparation method of tendon conjunction bone decellularization material of natural tissue source | |
CN105435307A (en) | Natural-tissue-derived decellularized and decalcified bone material and preparation method thereof | |
CN102225218B (en) | Method for preparing acellular dermal matrix by utilizing ultrasonic wave | |
Gu et al. | Preparation and evaluation of decellularized porcine carotid arteries cross-linked by genipin: the preliminary results | |
CN108245708A (en) | Bioactive scaffold for inducing tendon tissue regeneration and preparation method and application thereof | |
CN108578774A (en) | Brain tissue based on natural tissues source takes off the preparation method of cell material | |
CN106943628A (en) | A kind of meniscus in natural tissues source takes off cell material and preparation method thereof | |
CN107715177B (en) | Preparation method of nucleus pulposus cell modified porcine intestinal submucosa multiple decellularized material | |
CN110193096A (en) | A kind of marine origin biomimetic type cartilage material and preparation method thereof | |
CN109550082A (en) | A kind of preparation method of acellular matrix gel | |
CN109529120A (en) | A kind of small intestinal submucosa matrix repairs the preparation method of gel | |
JP6090990B2 (en) | Meniscal recycled substrate | |
WO2023040853A1 (en) | Periosteum-bone complex for reconstructing soft tissue-bone immune repair environment and preparation method therefor | |
CN108310466B (en) | A kind of preparation method of nucleus pulposus decellularized material derived from natural tissue | |
CN108514657A (en) | The muscle for being sustained IGF-1 growth factors takes off the preparation method of cell material | |
CN110680955B (en) | Decellularized material and preparation method of acellular biphasic aponeurotic muscle derived from natural tissue |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180831 |
|
RJ01 | Rejection of invention patent application after publication |